GM-CSF, Recombinant, Human, aa18-144 (CHO-expressed, CSF2)

Cat# 145701-10ug

Size : 10ug

Brand : US Biological



145701 Rabbit Anti-GM-CSF, Recombinant, Human, aa18-144 (CHO-expressed, CSF2)

Clone Type
Polyclonal
Swiss Prot
P04141
Grade
Highly Purified
Shipping Temp
Blue Ice
Storage Temp
-20°C

GM-CSF was initially characterized as a factor that can support the in vitro colony formation of granulocyte-macrophage progenitors. It is also a growth factor for erythroid, megakaryocyte, and eosinophil progenitors. GM-CSF is produced by a number of different cell types (including T cells, B cells, macrophages, mast cells, endothelial cells, fibroblasts, and adipocytes) in response to cytokine or inflammatory stimuli. On mature hematopoietic cells, GM-CSF is a survival factor for and activates the effector functions of granulocytes, monocytes/macrophages, and eosinophils (1, 2). GM-CSF promotes a Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity (3-5). It shows clinical effectiveness in ameliorating chemotherapy-induced neutropenia, and GM-CSF transfected tumor cells are utilized as cancer vaccines (6, 7). The 22kD glycosylated GM-CSF, similar to IL-3 and IL­5, is a cytokine with a core of four bundled alpha-helices (8-12). Mature human GM-CSF shares 63%-70% amino acid sequence identity with canine, feline, porcine, and rat GM-CSF and 54% with mouse GM-CSF. GM-CSF exerts its biological effects through a heterodimeric receptor complex composed of GM-CSF Ralpha/CD116 and the signal transducing common beta chain (CD131) which is also a component of the high-affinity receptors for IL-3 and IL-5 (13, 14). In addition, GM-CSF binds a naturally occurring soluble form of GM-CSF Ralpha (15). Human GM-CSF is active on canine and feline cells but not on murine cells (16-18).||Source:|Recombinant protein corresponding to aa18-144 from human GM-CSF, CHO-derived.||Molecular weight:|~20-35kD||Endotoxin:|<0.01EU/1ug (LAL method)||Storage and Stability:|Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O or PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Applications
Source: Recombinant, CHO cells|Purity: ≥95% (SDS­-PAGE)|Concentration: ~0.1mg/ml (after reconstitution)|Form: Supplied as a lyophilized powder in PBS, BSA. Reconstitute in 100ul PBS (>0.1% human or BSA).||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Form
Supplied as a lyophilized powder in PBS, BSA. Reconstitute in 100ul PBS (>0.1% human or BSA).
Purity
≥95% (SDS­-PAGE)
References
1. Martinez­Moczygemba, M. and D.P. Huston (2003) J. Allergy Clin. Immunol. 112:653. 2. Barreda, D.R. et al. (2004) Dev. Comp. Immunol. 28:509. 3. Eksioglu, E.A. et al. (2007) Exp. Hematol. 35:1163. 4. Cao, Y. (2007) J. Clin. Invest. 117:2362. 5. Fleetwood, A.J. et al. (2005) Crit. Rev. Immunol. 25:405. 6. Heuser, M. et al. (2007) Semin. Hematol. 44:148. 7. Hege, K.M. et al. (2006) Int. Rev. Immunol. 25:321. 8. Kaushansky, K. et al. (1992) Biochemistry 31:1881. 9. Diederichs, K. et al. (1991) Science 254:1779. 10. Cantrell, M.A. et al. (1985) Proc. Natl. Acad. Sci. 82:6250. 11. Lee, F. et al. (1985) Proc. Natl. Acad. Sci. 82:4360. 12. Wong, G.G. et al. (1985) Science 228:810. 13. Onetto­Pothier, N. et al. (1990) Blood 75:59. 14. Hayashida, K. et al. (1990) Proc. Natl. Acad. Sci. 87:9655. 15. Pelley, J.L. et al. (2007) Exp. Hematol. 35:1483. 16. Hogge, G.S. et al. (1990) Cancer Gene Ther. 6:26. 17. Sprague, W.S. et al. (2005) J. Comp. Pathol. 133:136. 18. Shanafelt, A.B. et al. (1991) J. Biol. Chem. 266:13804.